Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Computational Modeling of Individual Metabolic Pathways
Interventions: Not listed
Lead sponsor: Bioactify LLC; Other
Eligibility: Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Wappingers Falls, New York

Conditions: Healthy
Interventions: Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Gout
Interventions: Febuxostat XR; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Selpercatinib, Omeprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Treatment A, Treatment B, Treatment C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Metastatic Colorectal Cancer
Interventions: CA102N, TAS-102, Bevacizumab; Drug · Biological
Lead sponsor: Holy Stone Healthcare Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Gilbert, Arizona

Conditions: Malignant Neoplasm
Interventions: cytology specimen collection procedure, targeted therapy, therapeutic procedure, laboratory biomarker analysis; Other · Drug · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Participants
Interventions: H3B-6527; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Visual Acuity
Interventions: senofilcon A, delefilcon A; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 6
States / cities: Montgomery, Alabama • Jacksonville Beach, Florida • Longwood, Florida + 3 more

Conditions: Healthy
Interventions: Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole; Drug
Lead sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Schizophrenia
Interventions: Risperidone ISM® 100 mg; Drug
Lead sponsor: Rovi Pharmaceuticals Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Conditions: Cancer
Interventions: Custirsen, paclitaxel and carboplatin; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 1 more

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Visual Acuity
Interventions: ACUVUE® OASYS 1-DAY; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 7
States / cities: Jacksonville, Florida • Maitland, Florida • Tallahassee, Florida + 4 more

Conditions: Amyotrophic Lateral Sclerosis, Muscle Cramp
Interventions: TJ-68, Placebo; Drug
Lead sponsor: Hiroshi Mitsumoto; Other
Eligibility: 20 Years to 84 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • New York, New York

Conditions: Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
Interventions: Specialized tumor board recommendation; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 21 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 12
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions: ATLCAR.CD30 cells; Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 3 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2039
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Immunologic Deficiency Syndrome
Interventions: Immune Globulin Intravenous (Human); Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • Atlanta, Georgia + 3 more

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Polymerase Chain Reaction and Next-Generation DNA Sequencing; Diagnostic Test
Lead sponsor: MicroGenDX; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • San Diego, California • Camden, New Jersey + 1 more

Conditions: Healthy Adults (Full Study and Extension Phase), Hypertrophic Cardiomyopathy or Dilated Cardiomyopathy
Interventions: Family History + Whole Genome Sequencing, Family History Only; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Melanoma
Interventions: High Dose Interleukin-2, Ipilimumab; Drug
Lead sponsor: Clinigen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 9 more

Conditions: Diabetic Foot Ulcer, Diabetic Foot
Interventions: diabetic foot orthotic, Standard innersole; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cystic Fibrosis, Mucociliary Clearance Defect
Interventions: Baseline (Huff-Cough alone), Oscillatory Positive Expiatory Pressure Device, Whole-Body Vibration Platform, High Frequency Chest Wall Oscillatory Vest; Other · Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Lung Cancer Stage IV
Interventions: Blood and tumor tissue analysis, Clinical response.; Other
Lead sponsor: Holy Cross Hospital, Maryland; Other
Eligibility: 18 Years to 70 Years
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Silver Spring, Maryland

Search by objective public record fields.

Continuous N-of-1 Computational Feasibility Study of a Whole Genome Sequence

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

Food Effect Study of Febuxostat XR in Healthy Participants

A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants

A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol

CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer

Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer

A Study to Evaluate the Food-Effect of H3B-6527

A Comparison of Two Daily Disposable Soft Contact Lenses

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

Comparative Bioavailability of Risperidone

A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Clinical Evaluation of Senofilcon A Contact Lenses Using a Novel Manufacturing Technology

TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms

A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer

Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis

Personalizing Immune Checkpoint Inhibitor Therapy